Griffin Asset Management Inc. Cuts Stock Holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Griffin Asset Management Inc. decreased its holdings in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) by 14.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 257,679 shares of the company’s stock after selling 42,641 shares during the quarter. Griffin Asset Management Inc. owned 0.47% of Pulse Biosciences worth $2,883,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Pulse Biosciences by 28.8% in the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after buying an additional 189,227 shares in the last quarter. Westside Investment Management Inc. lifted its position in Pulse Biosciences by 97.8% in the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock valued at $712,000 after purchasing an additional 31,440 shares during the last quarter. Inspire Investing LLC lifted its position in Pulse Biosciences by 32.1% in the first quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock valued at $360,000 after purchasing an additional 10,039 shares during the last quarter. PNC Financial Services Group Inc. bought a new stake in Pulse Biosciences in the fourth quarter valued at approximately $242,000. Finally, Cetera Advisors LLC bought a new stake in Pulse Biosciences in the first quarter valued at approximately $109,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research report on Tuesday, August 6th.

Pulse Biosciences Price Performance

Shares of Pulse Biosciences stock traded down $0.30 during midday trading on Thursday, reaching $21.53. 118,724 shares of the company’s stock traded hands, compared to its average volume of 216,425. The stock has a 50 day moving average of $14.82 and a 200-day moving average of $11.17. Pulse Biosciences, Inc. has a 12 month low of $3.78 and a 12 month high of $22.21.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.